Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

Bayer symbol

Bayer UK launches digital educational hub to improve menopause support

An estimated 13 million women in the UK are currently perimenopausal or menopausal

- PMLiVE

Back to work

Supporting individuals when they return to work after an extended absence

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

- PMLiVE

BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial

Over 154,000 cases of colorectal cancer are expected to be diagnosed in the US in 2025

- PMLiVE

The silent treatment – researching gene silencing for Alzheimer’s, Parkinson’s and motor neurone disease

The science behind gene-silencing technology and the barriers and challenges faced by drug developers

- PMLiVE

What does HEOR really mean in 2025?

Global healthcare systems are under unprecedented strain. As life expectancies rise and populations age, the proportion of people aged 60+ years is expected to soar. This both signals remarkable progress...

Petauri Evidence

- PMLiVE

Meet the Petauri experts at World EPA Congress

We are delighted to announce that market access and HEOR experts from Mtech Access - Powered by Petauri will be attending World Evidence, Pricing and Access Congress in Amsterdam on...

Petauri Evidence

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

- PMLiVE

Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer

The combination was approved in the US last month to treat BRAF V600E-mutant disease

- PMLiVE

Havas Health Network launches Havas Life London

The agency will offer brand, corporate and cause-related communications in global health and rare diseases

- PMLiVE

Promiscuous strategists

Good strategists are good for other things too

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links